AMHR2

Across TCGA pan-cancer cohorts, AMHR2 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated AMHR2 data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher AMHR2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AMHR2 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

THYM, HNSC, and BRCA are the cancer types where AMHR2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
HNSC	OS	Median	All	0.169	0.751	<.001	42	view →
BRCA	OS	Median	All	0.144	0.579	<.001	26	view →
SARC	DFS	Median	All	0.086	0.611	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	OS	Median	II,III,IV	0.222	0.618	.006	6	view →
LIHC	OS	Median	All	0.031	0.775	<.001	6	view →
BLCA	OS	Median	All	0.472	0.721	.044	6	view →
STAD	DFS	Median	III,IV	1.000	0.324	.043	2	view →
UCEC	DFS	Median	All	0.914	0.621	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

AMHR2–THYM (OS)

Open the THYM breakdown →